Cellular and molecular pharmacology of oxaliplatin.

@article{Raymond2002CellularAM,
  title={Cellular and molecular pharmacology of oxaliplatin.},
  author={Eric Raymond and Sandrine J. Faivre and Stephen Chaney and Jan M. Woynarowski and Esteban Cvitkovic},
  journal={Molecular cancer therapeutics},
  year={2002},
  volume={1 3},
  pages={227-35}
}
Oxaliplatin, a diaminocyclohexane-containing platinum, has a spectrum of activity and mechanisms of action and resistance that appear to be different from those of other platinum-containing compounds, notably cisplatin. The first part of this review describes the differences between oxaliplatin and cisplatin in terms of their spectrum of activity and adduct formation and then goes on to discuss molecular and cellular experimental data that potentially explain them. Particular emphasis is placed… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 1 time. VIEW TWEETS

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 141 extracted citations

Oral poly(ADP-ribose) polymerase-1 inhibitor BSI-401 has antitumor activity and synergizes with oxaliplatin against pancreatic cancer, preventing acute neurotoxicity.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2009
View 4 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…